

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

PC 02/20

315562

Licensee

In accordance with letter dated **July 7, 2006**, and letter received **August 14, 2006**,

1. QHG of Indiana, Inc.

3. License number 13-01535-01 is amended in its entirety to read as follows:

2. 7950 West Jefferson Blvd.

4. Expiration date June 30, 2015

Fort Wayne, IN 46804-1677

5. Docket No. 030-01594

Reference No.

6. Byproduct, source, and/or special nuclear material

7. Chemical and/or physical form

8. Maximum amount that licensee may possess at any one time under this license

A. Any byproduct material permitted by 10 CFR 35.109

A. Any

A. As needed

B. Any byproduct material permitted by 10 CFR 35.200

B. Any

B. As needed

C. Any byproduct material permitted by 10 CFR 35.300


C. Any

C. As needed, not to exceed Curie of Iodine-131

D. Any byproduct material permitted by 10 CFR 35.400

D. Any

D. Curie



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
13-01535-01Docket or Reference Number
030-01594

Amendment No. 55

6. Byproduct, source, and/or special
nuclear materialE. Any byproduct material
permitted by 10 CFR 35.500F. Any byproduct material
permitted by 10 CFR 31.11

7. Chemical and/or physical form

E. Sealed Sources
(North American Scientific,
Inc., Models MED 3601
and Du Pont Merck
Pharmaceutical Company
NES-8412)

F. Prepackaged Kits

8. Maximum amount that licensee may
possess at any one time under this
licenseE. 300 millicurie per
source and 1200 millicuries
total

F. 1 millicuries

9. Authorized use:


A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.

B. Any imaging and localization study permitted by 10 CFR 35.200.

C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.

D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.

E. Diagnostic medical use of sealed sources permitted by 10 CFR 35.500 in compatible devices registered pursuant to 10 CFR 30.32(g).

F. In vitro studies.

10. Licensed material may be used or stored only at the licensee's facilities located at 7950 West Jefferson Boulevard, Fort Wayne, Indiana.

11. The Radiation Safety Officer for this license is Randall J. Phillips, M.D.

12. Licensed material is only authorized for use by, or under the supervision of:

A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

MATERIALS LICENSE SUPPLEMENTARY SHEET

License Number
13-01535-01

Docket or Reference Number
030-01594

Amendment No. 55

B. The following individuals are authorized users for medical use as indicated:

Authorized Users

Material and Use

| | |
|------------------------------|---|
| Brett A. Hagedorn, M.D. | 10 CFR 35.100, 35.200, 35.300 and 35.500. |
| John Rock, M.D. | 10 CFR 35.100, 35.200 and 31.11. |
| Rik Stephens, M.D. | 10 CFR 35.100, 35.200, 35.300, 35.500 and 31.11. |
| James C. Wehrenberg, M.D. | 10 CFR 35.100, 35.200, 35.500 and 31.11. |
| James A. Arata, M.D. | 10 CFR 35.100, 35.200, 35.300, 35.500 and 31.11. |
| David B. Janizek, M.D. | 10 CFR 35.100, 35.200, 35.300, 35.500 and 31.11. |
| Christine Anne Tremper, M.D. | 10 CFR 35.100, 35.200 (excluding xenon-133), 35.300 (limited to the treatment of hyperthyroidism) and 35.500. |
| Randall J. Phillips, M.D. | 10 CFR 35.100, 35.200, 35.300, 35.500 and 31.11. |
| John Pasalich, M.D. | 10 CFR 35.100, 35.200, 35.300 and 35.500. |
| Stephen R. Phillip, M.D. | 10 CFR 35.100, 35.200, 35.300 and 35.500. |
| Marc Thomas, M.D. | 10 CFR 35.100, 35.200, 35.300 and 35.500. |
| Diane D. Daly, M.D. | 10 CFR 35.100, 35.200, 35.300 and 35.500. |
| John L. Bormann, M.D. | 10 CFR 35.100, 35.200, 35.300 and 35.500. |
| Michael E. Parker, M.D. | 10 CFR 35.100, 35.200, 35.300 and 35.500. |
| Pamela Lee Strange, M.D. | 10 CFR 35.100, 35.200, 35.300 and 35.500. |
| Michael W. Tanksley, M.D. | 10 CFR 35.100, 35.200, 35.300 (excluding thyroid carcinoma therapy) and 35.500. |
| Joseph R. Decamp, M.D. | 10 CFR 35.100, 35.200 (excluding xenon-133), 35.300 (limited to the treatment of hyperthyroidism) and 35.500. |
| John R. Kim, M.D. | 10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma) and 35.500. |

MATERIALS LICENSE SUPPLEMENTARY SHEET

License Number
13-01535-01

Docket or Reference Number
030-01594

Amendment No. 55

Authorized Users

Material and Use

| | |
|------------------------------------|--|
| Frederick N. Vandeman, M.D. | 10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma) and 35.500. |
| Andre Byard Stovall, M.D. | 10 CFR 35.100, 35.200, 35.300 and 35.500. |
| Christopher Michael Kowalski, M.D. | 10 CFR 35.100, 35.200 and 35.500. |
| Gina W. Hook, M.D. | 10 CFR 35.100, 35.200 and 35.500. |
| Richard W. Sibley, M.D. | 10 CFR 35.100, 35.200, 35.300 and 35.500 |
| Dakshesh S. Patel, M.D. | 10 CFR 35.100, 35.200 and 35.500. |
| Eric V. Heatwole, M.D. | 10 CFR 35.100, 35.200 and 35.500. |
| Shilpa Kashyap, M.D. | 10 CFR 35.100, 35.200 and 35.500. |
| Deepchand Bajpai, M.D. | 10 CFR 35.300 and 35.400. |
| Rao V. P. Mantravadi, M.D. | 10 CFR 35.300 and 35.400. |
| James Gates, M.D. | 10 CFR 35.300 and 35.400. |
| Marc Apple, M.D. | 10 CFR 35.300. |
| Stephen Beyer, M.D. | 10 CFR 35.300. |
| Ralph W. Richardson, M.D. | 10 CFR 35.100, 35.200 and 35.500. |
| Shawn Johnson, M.D. | 10 CFR 35.100, 35.200, 35.300 |

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

13-01535-01

Docket or Reference Number

030-01594

Amendment No. 55

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated November 16, 2004; and
- B. Facsimile letter dated May 10, 2005.



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date AUG 17 2006

By

James R. Mullauer
James R. Mullauer, M.H.S.
Materials Licensing Branch
Region III